Showing 3901-3910 of 4165 results for "".
- New Data Presented on the Safety and Efficacy of Investigational AGN-190584 as a Potential Novel Treatment for Presbyopiahttps://modernod.com/news/new-data-presented-on-the-safety-and-efficacy-of-investigational-agn-190584-as-a-potential-novel-treatment-for-presbyopia/2479409/Allergan announced new data, including the full results from the phase 3 GEMINI 1 clinical study, evaluating the efficacy, safety and tolerability of investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia. Multiple data presentations at the 2021
- Modernizing Medicine Showcases Single-Screen Innovations at ASCRShttps://modernod.com/news/modernizing-medicine-showcases-single-screen-innovations-at-ascrs/2479405/Modernizing Medicine announced it has enhanced its electronic health records (EHR), EMA with functionality that can help to speed up documentation by removing steps in note-taking and allowing for quick editing, importing charts and more. These new and improved workflows for clinical docu
- Sight Sciences Announces Multiple Presentations at ASCRShttps://modernod.com/news/sight-sciences-announces-multiple-presentations-at-ascrs/2479400/Sight Sciences announced that data from multiple retrospective and prospective clinical studies of the OMNI Surgical System and TearCare System will be presented at the 2021 ASCRS Annual Meeting. The in-person conference will take place July 23-27 in Las Vegas. A total of five
- Monty Montoya Appointed CEO of TherOptixhttps://modernod.com/news/monty-montoya-appointed-ceo-of-theroptix/2479395/Monty Montoya has been named chief executive officer of TherOptix, a preclinical biopharma company focused on delivering clinically impactful therapeutics via a drug-eluting contact lens platform. TherOptix has received orphan drug designation on its lead candidate (001) for prevention of prolife
- EyePoint Pharmaceuticals Reports Positive 30-Day Safety Results for All Cohorts From DAVIO Trial of EYP-1901 for Wet AMDhttps://modernod.com/news/eyepoint-pharmaceuticals-reports-positive-30-day-safety-results-for-all-cohorts-from-the-davio-trial-of-eyp-1901-for-wet-amd/2479344/EyePoint Pharmaceuticals announced positive safety results from its phase 1 clinical trial of EYP-1901, a potential twice-yearly sustained delivery anti-VEGF treatment targeting wet age-related macular degeneration (AMD). All dose cohorts have reached at least 30-day post-dosing foll
- Iveric Bio Receives FDA Agreement Under Special Protocol Assessment (SPA) for Phase 3 Trial of Zimura in GA Secondary to AMDhttps://modernod.com/news/iveric-bio-receives-fda-agreement-under-special-protocol-assessment-spa-for-phase-3-trial-of-zimura-in-ga-secondary-to-amd/2479341/Iveric bio announced that the company received written agreement from the FDA under a Special Protocol Assessment (SPA) for the overall design of GATHER2, the company’s pivotal clinical trial of Zimura (avacincaptad pegol) in development for the treatment of geographic atrophy (GA) secondary to a
- Nicox Announces Last Patient Completed NCX 4251 Mississippi Phase 2b Blepharitis Trialhttps://modernod.com/news/nicox-announces-last-patient-completed-ncx-4251-mississippi-phase-2b-blepharitis-trial-2/2479337/Nicox SA announced that the last patient in the NCX 4251 Mississippi Phase 2b blepharitis clinical trial has now completed the two-week treatment phase, as well as the required two-week, follow-up period. Top-line results are expected to be announced in September 2021. “The Phase 2b Missis
- Nicox Announces Last Patient Completed NCX 4251 Mississippi Phase 2b Blepharitis Trialhttps://modernod.com/news/nicox-announces-last-patient-completed-ncx-4251-mississippi-phase-2b-blepharitis-trial/2479335/Nicox SA announced that the last patient in the NCX 4251 Mississippi phase 2b blepharitis clinical trial has now completed the 2-week treatment phase as well as the required 2-week follow up period. Topline results are expected to be announced in September 20
- GenSight Biologics Reports Topline Results From REFLECT Phase 3 Trial, Confirming Lumevoq Efficacyhttps://modernod.com/news/gensight-biologics-reports-topline-results-from-reflect-phase-3-trial-confirming-lumevoq-efficacy/2479336/GenSight Biologics reported key efficacy and safety findings at 1.5 years (78 weeks) post-treatment in the REFLECT phase 3 clinical trial for Lumevoq. The results show better visual acuity improvements from bilateral intravitreal injections of the gene therapy compared to a unilateral injection.<
- Nicox’s NCX 470 Demonstrates Significant Intraocular Pressure Lowering in Dolomites Phase 2 Glaucoma Trialhttps://modernod.com/news/nicoxs-ncx-470-demonstrates-significant-intraocular-pressure-lowering-in-dolomites-phase-2-glaucoma-trial/2479333/Nicox presented results from the Dolomites phase 2 clinical trial showing that NCX 470, a novel nitric oxide (NO)-donating prostaglandin analog (PGA), produced significantly greater IOP lowering effects in glaucoma patients compared with the current standard of care, latanoprost. In Dolom